Artificial intelligence (AI) continues to revolutionize the pharmaceutical and healthcare industries, and Fosun Pharma is emerging as a key player in this digital evolution. As a globally recognized innovation-driven healthcare group, Fosun Pharma is embracing AI to enhance drug discovery, medical imaging, precision medicine, marketing, and corporate operations. Through a blend of internal R&D and strategic alliances, the company is accelerating technological adoption across its enterprise, driving both productivity and innovation.
PharmAID: Fosun Pharma’s Proprietary AI Decision Intelligence Platform
Taking a major step forward, Fosun Pharma recently launched its self-developed PharmAID decision intelligence platform, designed to integrate AI-powered decision-making across the full drug development lifecycle. This platform incorporates cutting-edge large model technologies and is already integrated with the DeepSeek R1 model, marking it as a first-of-its-kind solution in the pharmaceutical industry.
PharmAID empowers teams with capabilities such as
- Predictive modeling
- Conformational analysis
- Binding mechanism insights
- Toxicity prediction
- Medical writing assistance
- Clinical data extraction
By supporting real-time decision-making and streamlining complex drug development tasks, the platform enhances both R&D efficiency and commercialization potential. PharmAID enables precise data interpretation and significantly boosts the accuracy and speed of drug pipeline evaluations.
Currently, the platform is integrated with numerous global clinical databases, boosting pharmaceutical content generation accuracy by 50% compared to general-purpose large language models. Daily data updates (T+1) ensure that content remains current and reliable.
PharmAID also enhances downstream operations such as AI-powered translation, medical writing, and salesforce training, equipping Fosun Pharma with smarter marketing tools and intelligent business applications. As AI becomes central to pharma competitiveness, PharmAID places Fosun at the forefront of digital healthcare transformation.
AI-Powered R&D and Strategic Alliances
Fosun Pharma’s investment in AI innovation began years ago. In 2022, the company partnered with Insilico Medicine, a pioneer in AI drug development, to explore AI-based discovery pipelines. More recently, in January 2025, Fosun Pharma’s subsidiary Henlius joined forces with DP Technology, integrating AI and physical modeling to enhance new drug R&D—especially for biologic antibodies, ADCs, and small molecule therapies targeting hard-to-reach mechanisms.
DP Technology’s AI-for-Science capabilities complement Henlius’ pharmaceutical expertise, paving the way for breakthroughs in drug design, simulation, and development timelines.
Fosun Aitrox: Building an AI+X Smart Healthcare Ecosystem
Fosun’s subsidiary Fosun Aitrox plays a pivotal role in building a next-generation “AI+X” healthcare ecosystem, offering comprehensive AI medical solutions across multiple specialties—radiology, pathology, ultrasound, neurology, cardiology, orthopedics, and more.
Its AI-powered diagnostic tools are clinically validated and deployed at scale, with flagship products in
- Radiology imaging
- Pathology imaging
- Ultrasound imaging
These tools enable clinicians to rapidly analyze medical data, improve diagnostic accuracy, and shorten time to treatment—especially in remote or under-resourced areas. Fosun Aitrox’s AI solutions are now present in over 70% of China, operating in 20+ provinces and powering nearly 10 regional smart healthcare demonstration zones.
The company has launched or is developing more than 70 AI healthcare products, many of which have won top honors in global AI competitions.
Augmented Reality Surgery: JeDiCare’s Breakthrough in Minimally Invasive Technology
Further strengthening its AI portfolio, Fosun Pharma-backed startup JeDiCare is innovating in surgical navigation. By fusing augmented reality (AR) with monocular vision tracking, JeDiCare has developed a proprietary AR-guided puncture navigation system, currently under regulatory review.
This device enables precise surgical targeting during minimally invasive procedures, significantly improving accuracy while reducing complexity. Its eventual deployment will empower primary care hospitals to perform high-precision thoracoscopic surgeries, bringing advanced care to underserved regions.
Vision for the Future: Full-Chain AI Innovation Across Healthcare
Looking ahead, Fosun Pharma remains committed to scaling AI applications across the entire pharmaceutical value chain. By balancing independent innovation with external partnerships, the company is set to lead the industry’s digital transformation while enhancing global healthcare outcomes.
From clinical trials to diagnosis, sales enablement to surgery, AI is deeply woven into Fosun Pharma’s strategic vision—aiming to deliver faster, more accurate, and more accessible medical solutions worldwide.
About Fosun Pharma
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a globally oriented pharmaceutical and healthcare group, spanning pharmaceuticals, medical devices, diagnostics, and healthcare services. Fosun Pharma also holds a stake in Sinopharm Co., Ltd., expanding its reach into pharmaceutical distribution and retail.
The company is guided by its “4IN” strategy—Innovation, Internationalization, Intelligentization, and Integration—and a corporate mission of “Innovation for Good Health.” By prioritizing patient needs and technological advancement, Fosun Pharma is continuously expanding its product pipeline, with a focus on solid tumors, hematologic cancers, autoimmune diseases, and high-barrier biologics.
With a blend of R&D investment, global expansion, and AI integration, Fosun Pharma aims to become the world’s leading integrator of pharmaceutical and healthcare innovation.
